Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
16.25
-0.23 (-1.40%)
At close: May 22, 2026, 4:00 PM EDT
16.24
-0.01 (-0.06%)
After-hours: May 22, 2026, 7:58 PM EDT
Takeda Pharmaceutical Revenue
In the fiscal year ending March 31, 2026, Takeda Pharmaceutical had annual revenue of 4.51T JPY, down -1.66%. Takeda Pharmaceutical had revenue of 1.09T in the quarter ending March 31, 2026, with 3.90% growth.
Revenue (ttm)
4.51T JPY
Revenue Growth
-1.66%
P/S Ratio
1.79
Revenue / Employee
94,947,213 JPY
Employees
47,455
Market Cap
50.67B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.51T | -75.83B | -1.66% |
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.20B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.35B |
| Haleon | 14.85B |
| Viatris | 14.56B |
| Zoetis | 9.53B |
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.58B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
TAK News
- 2 days ago - Takeda Pharmaceutical is Now Oversold (TAK) - Nasdaq
- 6 days ago - Takeda Ordered To Pay $884.9 Mln In AMITIZA Antitrust Case; To Revise FY25 Results - Nasdaq
- 6 days ago - Takeda Pharmaceutical (TAK) Found Guilty in Generic Drug Delay Conspiracy - GuruFocus
- 6 days ago - Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda - Business Wire
- 6 days ago - Jury finds Takeda caused about $885M in damages over generic delay, Reuters says - TheFly
- 6 days ago - Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds - Reuters
- 6 days ago - Takeda told to pay hundreds of millions for generic drug delay, Bloomberg says - TheFly
- 6 days ago - Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says - TheFly